A case of hemolytic-uremic syndrome with the development of catastrophic antiphospholipid syndrome: Diagnosis and clinical tactics


如何引用文章

全文:

详细

The paper describes a case of practically simultaneous development of the hemolytic-uremic syndrome (HUS) and the catastrophic antiphospholipid syndrome (CAPS) complicated by mesenteric vessel thrombosis and small bowel necrosis. Multimodality treatment comprising volume plasmapheresis, fresh frozen plasma transfusion, hemodialysis, anticoagulant and disaggregant therapy could relieve thrombogenic events, such as pulmonary artery thromboembolism and intestinal necrosis.

参考

  1. Панков Е. А., Папаян А. В., Куаншкалиев Р. С. Исследование функционального состояния почек в ближайшем и отдаленном катамнезе у детей, перенесших гемолитико-уремический синдром. В кн.: Материалы Всероссийской науч.-практ. конф. "Проблемы детской нефрологии". М.; 1997: 79.
  2. Bielaszewska M., Zhang W., Mellmann A., Karch H. Enterohaemorrhagic Escherichia coli O26:H11/H-: a human pathogen in emergence. Berl. Münch. Tierarztl. Wschr. 2007; 120(7-8): 279-287.
  3. Boyce T. G., Swerdlow D. L., Griffin P. M. Escherichia coli 0157:H7 and the hemolytic uremic syndrome. N. Engl. J. Med. 1995; 333: 364-368.
  4. McRegan S., Chesney R., Kaplan B., Drummond K. Red cell membrane phospholipid abnormalities in the haemolytic uremic syndrome. Clin. Nephrol. 1981; l5: 14-17.
  5. Karch H., Friedrich A. W., Gerber A. et al. New aspects in the pathogenesis of enteropathic hemolytic uremic syndrome. Semin. Thromb. Hemost. 2006; 32(2): 105-112.
  6. Harel Y., Silva M., Giroir B. et al. A reporter transgene indicates renal-specific induction of tumour necrosis factor (TNF) by Shiga-like toxin. J. Clin. Invest. 1993; 92: 2110-2116.
  7. Inward C. D., Varagunam M., Adu D. et al. Cytokines in haemolytic uremic syndrome associated with verocytotoxin-producing Escherichia coli infection. Arch. Dis. Child. 1997; 77; 145-147.
  8. Obrig T. G., Louise C. B., Lingwood C. A. et al. Endothelial heterogeneity in Shiga toxin receptors and responses. J. Biol. Chem. 1993; 268: 15484-15488.
  9. Reid J. L., Dawson D., Macral I. M. Endothelin, cerebral ischemia and infarction. Clin. Exp. Hypertens. 1995; 17: 399- 407.
  10. Kohan D. E. Endothelins in the normal and diseased kidney. Am. J. Kidney Dis. 1997; 29: 2-26.
  11. Kuhn M., Fuchs M., Beck F. et al. Endothelin-1 potently stimulates chloride secretion and inhibits Na(+)-glucose absorbtion in human intestine in vitro J. Physiol. (Lond.). 1996; 499: 391-402.
  12. Turi S., Nemeth I., Vargha I., Matkovics B. Oxidative damage of red blood cells in haemolytic uremic syndrome. Pediatr. Nephrol. 1994; 8: 26-29.
  13. Espinosa G., Bucciarelli S., Cervera R. et al. Thrombotic microangiopathic anemia and antiphospholipid antibodies. Ann. Rheum. Dis. 2004; 63(6): 730-736.
  14. Asherson R. A. The catastrophic antiphospholipid syndrome. (Asherson's syndrome). Johannesburg; 2005.
  15. Asherson R. A., Cervera R., Piette J. C. et al. Catastrophic antiphospholipid syndrome: clues to the pathogenesis from the series of 80 patients. Medicine (Baltimore) 2001; 80(6): 355- 377.
  16. Cervera R., Font J., Gomez-Puerta J. A. et al. Catastrophic antiphospholipid syndrome Registry Project Group. Validation of the preliminary criteria for the classification of catastrophic antiphospholipid syndrome. Ann. Rheum. Dis. 2005; 64: 1205-1209.
  17. del Papa N., Guidali L., Salq Q. et al. Endothelial cell as target for antiphospholipid antibodies. Arthr. and Rheum. 1997; 40: 551-561.
  18. Vora S. K., Asherson R. A., Erkan D. Catastrophic antiphospholipid syndrome. J. Int. Care Med. 2006; 2l: 144-159.
  19. Von Tempelhoff G. E., Heilmann L., Spanuth E. et al. Incidence of the factor V Leiden-mutation, coagulation inhibitor deficiency, and elevated antiphospholipid-antibodies in patients with preeclampsia or HELLP-syndrome. Hemolysis, elevated liver-enzymes, low platelets. Thromb. Res. 2000; 100(4): 363-365.
  20. Макацария А. Д., Бицадзе В. О., Акиньшина С. В. Тромбозы и тромбоэмболии в акушерско-гинекологической клинике. Молекулярно-генетические механизмы и стратегия профилактики тромбоэмболических осложнений: Руководство для врачей. М.: МИА; 2007.

补充文件

附件文件
动作
1. JATS XML
下载

版权所有 © Consilium Medicum, 2010

Creative Commons License
此作品已接受知识共享署名-非商业性使用-相同方式共享 4.0国际许可协议的许可。
 

Address of the Editorial Office:

  • Alabyan Street, 13/1, Moscow, 127055, Russian Federation

Correspondence address:

  • Alabyan Street, 13/1, Moscow, 127055, Russian Federation

Managing Editor:

  • Tel.: +7 (926) 905-41-26
  • E-mail: e.gorbacheva@ter-arkhiv.ru

 

 © 2018-2021 "Consilium Medicum" Publishing house